Ark Biosciences to Present Efficacy Data on Novel Ziresovir at an International Conference
Ark Biosciences (Ark) to present efficacy data on its novel RSV F-protein inhibitor, Ziresovir (AK0529) at the 11th International RSV Symposium in Asheville, North Carolina, USA, 31st October – 4th November 2018
Ark has submitted an abstract reporting single dose clinical efficacy of its novel RSV F-protein inhibitor Ziresovir, formerly known as AK0529, in infants hospitalized for lower respiratory tract infection with naturally acquired RSV infection. The data to be presented is from the Phase II ‘VICTOR (Viral Inhibition in Children for Treatment of RSV)’ study, “A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection”.
Popular recommendations
-
Ark Biopharmaceutical Presents Positive Results in Phase 3 AIRFLO Study of Ziresovir in RSV-Infected Hospitalized Infants at 12th International RSV Symposium2022-10-07
-
ArkBio Announces Publication of Phase 3 Clinical Trial Results of Ziresovir for the Treatment of RSV Infection in The New England Journal of Medicine2024-09-27
-
ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection2024-11-25
-
ArkBio Presented at the 8th Annual IPF Summit and Announced Completion of Patient Enrollment for Phase 2 Clinical Trial of AK3280, a Next-Generation Drug for IPF Treatment2024-08-26
-
ArkBio is listed in the "2023 Top 50 Most Investable Healthcare Companies"2024-05-15
-
ArkBio and Tongji Medical College of Huazhong University of Science and Technology and Hubei CDC Jointly Publish a Paper on a New Anti-SARS-CoV-2 Inhibitor in "Journal of Infection"2024-02-20
